According to the Futu Securities app, Bank of America Securities released a research report stating that sh pharma (02607) maintained a steady performance in the healthcare services business in the second quarter, but due to the pressure on distribution business, the revenue forecast for fiscal years 2024 to 2026 has been lowered by 8%, 12%, and 14% respectively. The earnings per share forecast has also been adjusted to 1.13 yuan, 1.22, and 1.33 yuan, and the listed in hong kong target price has been reduced from 13.9 Hong Kong dollars to 13.7 Hong Kong dollars. Considering the continuous improvement in operational efficiency at sh pharma, the bank has reduced its sales expense forecast for fiscal year 2024 and beyond. Taking into account these factors, as well as sh pharma's leading position in the industry, the review maintains a "buy" rating.